Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV

Downloaded from https://aidsinfo.nih.gov/guidelines on 5/17/2020

Visit the AIDStinfo website to access the most up-to-date guideline.

Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.
### Appendix B, Table 8. Characteristics of the CCR5 Antagonist  
(Latest updated March 27, 2012; last reviewed July 10, 2019)

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Serum Half-Life</th>
<th>Elimination/ Metabolic Pathway</th>
<th>Adverse Events</th>
</tr>
</thead>
</table>
| Maraviroc (MVC) Selzentry    | Selzentry: 150 and 300 mg tablets | Selzentry:  
- MVC 150 mg twice daily when given with drugs that are strong CYP3A inhibitors (with or without CYP3A inducers), including PIs (except TPV/r)  
- MVC 300 mg twice daily when given with NRTIs, T-20, TPV/r, NVP, RAL, and other drugs that are not strong CYP3A inhibitors or inducers  
- MVC 600 mg twice daily when given with drugs that are CYP3A inducers, including EFV, ETR, etc. (without a CYP3A inhibitor)  
Take MVC without regard to meals. | 14–18 hours | CYP3A4 substrate | Abdominal pain  
Cough  
Dizziness  
Musculoskeletal symptoms  
Pyrexia  
Rash  
Upper respiratory tract infections  
Hepatotoxicity, which may be preceded by severe rash or other signs of systemic allergic reactions  
Orthostatic hypotension, especially in patients with severe renal insufficiency |

*A For dose adjustments in patients with hepatic insufficiency, see Appendix B, Table 10.

*B Also see Table 17.

**Key:** CYP = cytochrome P; EFV = efavirenz; ETR = etravirine; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; RAL = raltegravir; T-20 = enfuvirtide; TPV/r = tipranavir/ritonavir

### Appendix B, Table 9. Characteristics of the CD4 Post-Attachment Inhibitor  
(Last updated July 10, 2019; last reviewed July 10, 2019)

<table>
<thead>
<tr>
<th>Generic Name (Abbreviation)</th>
<th>Formulation</th>
<th>Dosing Recommendations</th>
<th>Serum Half-Life</th>
<th>Elimination/ Metabolic Pathway</th>
<th>Adverse Events</th>
</tr>
</thead>
</table>
| Ibalizumab (IBA) Trogarzo   | Trogarzo: Single-dose 2 mL vial containing 200 mg/1.33 mL (150 mg/mL) of ibalizumab | Trogarzo:  
- Administer a single loading dose of IBA 2,000 mg IV infusion over 30 minutes, followed by a maintenance dose of IBA 800 mg IV infusion over 15 minutes every 2 weeks.  
- See prescribing information for additional instructions for preparing, storing, and administering IBA, and for monitoring patients who are receiving IBA. | ~64 hours | Not well defined | Diarrhea  
Dizziness  
Nausea  
Rash |

**Key:** IBA = ibalizumab; IV = intravenous